Bacteria under stress by complement and coagulation

FEMS Microbiology Reviews

Volumn 38, Issue 6, 2014, Pages 1146-1171

  Berends, Evelien T M ^a   Kuipers, Annemarie ^a   Ravesloot, Marietta M ^a   Urbanus, Rolf T ^a   Rooijakkers, Suzan H M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bacteria; Coagulation; Complement; Evasion; Innate immunity; Membrane attack complex

Indexed keywords

BLOOD CLOTTING FACTOR; COMPLEMENT; COMPLEMENT MEMBRANE ATTACK COMPLEX; LIPOPOLYSACCHARIDE; POLYPEPTIDE ANTIBIOTIC AGENT;

ACUTE PHASE RESPONSE; ANTIMICROBIAL ACTIVITY; BACTERIAL CELL; BACTERIAL STRUCTURES; BACTERICIDAL ACTIVITY; BACTERIUM; BLOOD CLOTTING; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; COMPLEMENT SYSTEM; COVALENT BOND; CYTOTOXIC T LYMPHOCYTE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMOSTASIS; HOST RESISTANCE; IN VITRO STUDY; INNATE IMMUNITY; MAMMAL; NEISSERIA MENINGITIDIS; NONHUMAN; OUTER MEMBRANE; PROTEIN BINDING; PSEUDOMONAS AERUGINOSA; REVIEW; STREPTOCOCCUS PNEUMONIAE; TARGET CELL; UPREGULATION; BACTERIA; BACTERIAL INFECTION; BACTERIAL PHENOMENA AND FUNCTIONS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MICROBIOLOGY; PHYSIOLOGICAL STRESS;

BACTERIA (MICROORGANISMS); MAMMALIA;

BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PHYSIOLOGICAL PHENOMENA; BLOOD COAGULATION; COMPLEMENT SYSTEM PROTEINS; HOST-PATHOGEN INTERACTIONS; STRESS, PHYSIOLOGICAL;

EID: 84924923424     PISSN: 01686445     EISSN: 15746976     Source Type: Journal    
DOI: 10.1111/1574-6976.12080     Document Type: Review

References (275)

1. Ahrenholz D & Simmons R (1980) Fibrin in peritonitis. I. Beneficial and adverse effects of fibrin in experimental E. coli peritonitis. Surgery 88: 41-47.
2. Akesson P, Herwald H, Rasmussen M, Håkansson K, Abrahamson M, Hasan AAK, Schmaier AH, Müller-Esterl W & Björck L (2010) Streptococcal inhibitor of complement-mediated lysis (SIC): an anti-inflammatory virulence determinant. Microbiology 156: 3660-3668.
3. Albertí S, Marqués G, Camprubí S, Merino S, Tomás JM, Vivanco F & Benedí VJ (1993) C1q binding and activation of the complement classical pathway by Klebsiella pneumoniae outer membrane proteins. Infect Immun 61: 852-860.
4. Aleshin AE, Schraufstatter IU, Stec B, Bankston La, Liddington RC & Discipio RG (2012) Structure of complement C6 suggests a mechanism for initiation and unidirectional, sequential assembly of the Membrane Attack Complex (MAC). J Biol Chem 287: 10210-10222.
5. Ali YM, Lynch NJ, Haleem KS et al. (2012) The lectin pathway of complement activation is a critical component of the innate immune response to pneumococcal infection. PLoS Pathog 8: e1002793.
6. Amara U, Flierl MA, Rittirsch D et al. (2010) Molecular intercommunication between the complement and coagulation systems. J Immunol 185: 5628-5636.
7. An J-H, Kurokawa K, Jung D-J, Kim M-J, Kim C-H, Fujimoto Y, Fukase K, Coggeshall KM & Lee BL (2013) Human SAP is a novel peptidoglycan recognition protein that induces complement-independent phagocytosis of Staphylococcus aureus. J Immunol 191: 3319-3327.
8. Attia AS, Ram S, Rice PA & Hansen EJ (2006) Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the complement cascade. Infect Immun 74: 1597-1611.
9. Bajic G, Yatime L, Sim RB, Vorup-jensen T & Andersen GR (2013) Structural insight on the recognition of surface-bound opsonins by the integrin I domain of complement receptor 3. P Natl Acad Sci USA 110: 16426-16431.
10. Bardoel BW & Strijp JAG (2011) Molecular battle between host and bacterium: recognition in innate immunity. J Mol Recognit 24: 1077-1086.
11. Barthel D, Singh B, Riesbeck K & Zipfel PF (2012) Haemophilus influenzae uses the surface protein E to acquire human plasminogen and to evade innate immunity. J Immunol 188: 379-385.
12. Bayer ME (1968) Areas of adhesion between wall and membrane of Escherichia coli. J Gen Microbiol 53: 395-404.
13. Ben Nasr A, Olsén A, Sjöbring U, Müller-Esterl W & Björck L (1996) Assembly of human contact phase proteins and release of bradykinin at the surface of curli-expressing Escherichia coli. Mol Microbiol 20: 927-935.
14. Bengtson SH, Sandén C, Mörgelin M, Marx PF, Olin AI, Leeb-Lundberg LMF, Meijers JCM & Herwald H (2009) Activation of TAFI on the surface of Streptococcus pyogenes evokes inflammatory reactions by modulating the kallikrein/kinin system. J Innate Immun 1: 18-28.
15. Berends ETM, Dekkers JF, Nijland R, Kuipers A, Soppe JA, van Strijp JAG & Rooijakkers SHM (2013) Distinct localization of the complement C5b-9 complex on Gram-positive bacteria. Cell Microbiol 15: 1955-1968.
16. Bergmann S, Rohde M, Chhatwal GS & Hammerschmidt S (2001) alpha-Enolase of Streptococcus pneumoniae is a plasmin(ogen)-binding protein displayed on the bacterial cell surface. Mol Microbiol 40: 1273-1287.
17. Bestebroer J, Aerts PC, Rooijakkers SHM, Pandey MK, Köhl J, van Strijp JAG & de Haas CJC (2010) Functional basis for complement evasion by staphylococcal superantigen-like 7. Cell Microbiol 12: 1506-1516.
18. Biesecker G, Gerard C & Hugli TE (1982) An amphiphilic structure of the ninth component of human complement. J Biol Chem 257: 2584-2590.
19. Bliska JB & Falkow S (1992) Bacterial resistance to complement killing mediated by the Ail protein of Yersinia enterocolitica. P Natl Acad Sci USA 89: 3561-3565.
20. Blom AM, Hallström T & Riesbeck K (2009) Complement evasion strategies of pathogens-acquisition of inhibitors and beyond. Mol Immunol 46: 2808-2817.
21. Blombäck B, Hessel B, Hogg D & Therkildsen L (1978) A two-step fibrinogen-fibrin transition in blood coagulation. Nature 275: 501-505.
22. Bolitho P, Voskoboinik I, Trapani JA & Smyth MJ (2007) Apoptosis induced by the lymphocyte effector molecule perforin. Curr Opin Immunol 19: 339-347.
23. Born J & Bhakdi S (1986) Does complement kill E. coli by producing transmural pores? Immunology 59: 139-145.
24. Brissette CA, Haupt K, Barthel D, Cooley AE, Bowman A, Skerka C, Wallich R, Zipfel PF, Kraiczy P & Stevenson B (2009) Borrelia burgdorferi infection-associated surface proteins ErpP, ErpA, and ErpC bind human plasminogen. Infect Immun 77: 300-306.
25. Van Burgel ND, Kraiczy P, Schuijt TJ, Zipfel PF & van Dam AP (2010) Identification and functional characterisation of Complement Regulator Acquiring Surface Protein-1 of serum resistant Borrelia garinii OspA serotype 4. BMC Microbiol 10: 43.
26. Caroff M, Karibian D, Cavaillon JM & Haeffner-Cavaillon N (2002) Structural and functional analyses of bacterial lipopolysaccharides. Microbes Infect 4: 915-926.
27. Carroll MC & Isenman DE (2012) Regulation of humoral immunity by complement. Immunity 37: 199-207.
28. Cascales E, Buchanan SK, Duché D, Kleanthous C, Lloubès R, Postle K, Riley M, Slatin S & Cavard D (2007) Colicin biology. Microbiol Mol Biol Rev 71: 158-229.
29. Catalão MJ, Gil F, Moniz-Pereira J, São-José C & Pimentel M (2013) Diversity in bacterial lysis systems: bacteriophages show the way. FEMS Microbiol Rev 37: 554-571.
30. Chen R & Doolittle RF (1971) γ-γ cross-linking sites in human and bovine fibrin. Biochemistry 10: 4486-4491.
31. Cheng AG, McAdow M, Kim HK, Bae T, Missiakas DM & Schneewind O (2010) Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog 6: e1001036.
32. Chung MC, Tonry JH, Narayanan A et al. (2011) Bacillus anthracis interacts with plasmin(ogen) to evade C3b-dependent innate immunity. PLoS ONE 6: e18119.
33. Citarella F, Wuillemin WA, Lubbers YT & Hack CE (1997) Initiation of contact system activation in plasma is dependent on factor XII autoactivation and not on enhanced susceptibility of factor XII for kallikrein cleavage. Br J Haematol 99: 197-205.
34. Cooper NR & Morrison DC (1978) Binding and activation of the first component of human complement by the lipid A region of lipopolysaccharides. J Immunol 120: 1862-1868.
35. Du Clos TW (2013) Pentraxins: structure, function, and role in inflammation. ISRN Inflamm 2013: 379040.
36. Colman RW & Schmaier AH (1997) Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 90: 3819-3843.
37. Cooper NR & Müller-Eberhard HJ (1970) The reaction mechanism of human C5 in immune hemolysis. J Exp Med 132: 775-793.
38. Cortes C, Ferreira VP & Pangburn MK (2011) Native properdin binds to Chlamydia pneumoniae and promotes complement activation. Infect Immun 79: 724-731.
39. Cramer WA, Heymann JB, Schendel SL, Deriy BN, Cohen FS, Elkins PA & Stauffacher CV (1995) Structure-function of the channel-forming colicins. Annu Rev Biophys Biomol Struct 24: 611-641.
40. Dankert JR & Esser AF (1987) Bacterial killing by complement. C9-mediated killing in the absence of C5b-8. Biochem J 244: 393-399.
41. Dankert JR & Esser AF (1986) Complement-mediated killing of Escherichia coli: dissipation of membrane potential by a C9-derived peptide. Biochemistry 25: 1094-1100.
42. Demchick P & Koch AL (1996) The permeability of the wall fabric of Escherichia coli and Bacillus subtilis. J Bacteriol 178: 768-773.
43. DiRienzo JM, Nakamura K & Inouye M (1978) The outer membrane proteins of Gram-negative bacteria: biosynthesis, assembly, and functions. Annu Rev Biochem 47: 481-532.
44. DiScipio RG & Hugli TE (1985) The architecture of complement component C9 and poly(C9). J Biol Chem 260: 14802-14809.
45. DiScipio RG, Smith CA, Müller-Eberhard HJ & Hugli TE (1983) The activation of human complement component C5 by a fluid phase C5 convertase. J Biol Chem 258: 10629-10636.
46. Dobó J, Major B, Kékesi KA, Szabó I, Megyeri M, Hajela K, Juhász G, Závodszky P & Gál P (2011) Cleavage of kininogen and subsequent bradykinin release by the complement component: mannose-binding lectin-associated serine protease (MASP)-1. PLoS ONE 6: e20036.
47. Duensing TD & Putten JPM (1998) Vitronectin binds the gonococcal adhesin OpaA through a glycosaminoglycan molecular bridge. Biochem J 139: 133-139.
48. Dunkelberger JR & Song W-C (2010) Role and mechanism of action of complement in regulating T cell immunity. Mol Immunol 47: 2176-2186.
49. Esmon CT (2004) Interactions between the innate immune and blood coagulation systems. Trends Immunol 25: 536-542.
50. Esser AF (1994) The membrane attack complex of complement. Assembly, structure and cytotoxic activity. Toxicology 87: 229-247.
51. Estabrook MM, Griffiss JM & Jarvis GA (1997) Sialylation of Neisseria meningitidis lipooligosaccharide inhibits serum bactericidal activity by masking lacto-N-neotetraose. Infect Immun 65: 4436-4444.
52. Farkas I, Baranyi L, Ishikawa Y, Okada N, Bohata C, Budai D, Fukuda A, Imai M & Okada H (2002) CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9. J Physiol 9: 537-545.
53. Felding-Habermann B & Cheresh DA (1993) Vitronectin and its receptors. Curr Opin Cell Biol 5: 864-868.
54. Fitzgerald JR, Loughman A, Keane F, Brennan M, Knobel M, Higgins J, Visai L, Speziale P, Cox D & Foster TJ (2006) Fibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcgammaRIIa receptor. Mol Microbiol 59: 212-230.
55. Flick MJ, Du X & Degen JL (2004) Fibrin(ogen)-alpha M beta 2 interactions regulate leukocyte function and innate immunity in vivo. Exp Biol Med 229: 1105-1110.
56. Floden AM, Watt JA & Brissette CA (2011) Borrelia burgdorferi enolase is a surface-exposed plasminogen binding protein. PLoS ONE 6: e27502.
57. Frick I, Björck L & Herwald H (2007) The dual role of the contact system in bacterial infectious disease. Thromb Haemost 98: 497-502.
58. Frick I-M, Akesson P, Herwald H, Mörgelin M, Malmsten M, Nägler DK & Björck L (2006) The contact system-a novel branch of innate immunity generating antibacterial peptides. EMBO J 25: 5569-5578.
59. Frick I-M, Shannon O, Åkesson P, Mörgelin M, Collin M, Schmidtchen A & Björck L (2011) Antibacterial activity of the contact and complement systems is blocked by SIC, a protein secreted by Streptococcus pyogenes. J Biol Chem 286: 1331-1340.
60. Friedrich R, Panizzi P, Fuentes-Prior P, Richter K, Verhamme I, Anderson PJ, Kawabata S, Huber R, Bode W & Bock PE (2003) Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 425: 535-539.
61. Fujita T, Matsushita M & Endo Y (2004) The lectin-complement pathway - its role in innate immunity and evolution. Immunol Rev 198: 185-202.
62. García D, Mañas P, Gómez N, Raso J & Pagán R (2006) Biosynthetic requirements for the repair of sublethal membrane damage in Escherichia coli cells after pulsed electric fields. J Appl Microbiol 100: 428-435.
63. Ghebrehiwet B, Silverberg M & Kaplan AP (1981) Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 153: 665-676.
64. Granoff DM (2009) Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine 27(suppl 2): B117-B125.
65. Griffiths NJ, Hill DJ, Borodina E, Sessions RB, Devos NI, Feron CM, Poolman JT & Virji M (2011) Meningococcal surface fibril (Msf) binds to activated vitronectin and inhibits the terminal complement pathway to increase serum resistance. Mol Microbiol 82: 1129-1149.
66. Gros P, Milder FJ & Janssen BJC (2008) Complement driven by conformational changes. Nat Rev Immunol 8: 48-58.
67. Grossman N, Schmetz MA, Foulds J, Klima EN, Jimenez-Lucho VE, Leive LL, Joiner KA & Jiminez V (1987) Lipopolysaccharide size and distribution determine serum resistance in Salmonella montevideo. J Bacteriol 169: 856-863.
68. Guggenberger C, Wolz C, Morrissey JA & Heesemann J (2012) Two distinct coagulase-dependent barriers protect Staphylococcus aureus from neutrophils in a three dimensional in vitro infection model. PLoS Pathog 8: e1002434.
69. Gulla KC, Gupta K, Krarup A, Gal P, Schwaeble WJ, Sim RB, O'Connor CD & Hajela K (2010) Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology 129: 482-495.
70. Guo R-F & Ward PA (2005) Role of C5a in inflammatory responses. Annu Rev Immunol 23: 821-852.
71. Haas P-J & Strijp JA (2007) Anaphylatoxins Their role in bacterial infection and inflammation. Immunol Res 37: 161-175.
72. Hadders MA, Bubeck D, Roversi P, Hakobyan S, Forneris F, Morgan BP, Pangburn MK, Llorca O, Lea SM & Gros P (2012) Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9. Cell Rep 1: 200-207.
73. Hadders MA, Beringer DX & Gros P (2007) Structure of C8alpha-MACPF reveals mechanism of membrane attack in complement immune defense. Science 317: 1552-1554.
74. Hallström T, Siegel C, Mörgelin M, Kraiczy P, Skerka C & Zipfel PF (2013) CspA from Borrelia burgdorferi inhibits the terminal complement pathway. mBio 4: e00481-13.
75. Hallström T, Trajkovska E, Forsgren A & Riesbeck K (2006) Haemophilus influenzae surface fibrils contribute to serum resistance by interacting with vitronectin. J Immunol 177: 430-436.
76. Hansen S, Selman L, Palaniyar N et al. (2010) Collectin 11 (CL-11, CL-K1) is a MASP-1/3-associated plasma collectin with microbial-binding activity. J Immunol 185: 6096-6104.
77. Harboe M, Garred P, Lindstad JK, Pharo A, Müller F, Stahl GL, Lambris JD & Mollnes TE (2012) The role of properdin in zymosan- and Escherichia coli-induced complement activation. J Immunol 189: 2606-2613.
78. Haupt K, Kraiczy P, Wallich R, Brade V, Skerka C & Zipfel PF (2007) Binding of human factor H-related protein 1 to serum-resistant Borrelia burgdorferi is mediated by borrelial complement regulator-acquiring surface proteins. J Infect Dis 196: 124-133.
79. Heffernan EJ, Reed S, Hackett J, Fierer J, Roudier C & Guiney D (1992) Mechanism of resistance to complement-mediated killing of bacteria encoded by the Salmonella typhimurium virulence plasmid gene rck. J Clin Invest 90: 953-964.
80. Heinen S, Hartmann A, Lauer N et al. (2009) Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 114: 2439-2447.
81. Helmy KY, Katschke KJ, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, Scales SJ, Ghilardi N & van Lookeren Campagne M (2006) CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124: 915-927.
82. Herwald H, Mörgelin M, Olsén A, Rhen M, Dahlback B, Müller-Esterl W & Björck L (1998) Activation of the contact-phase system on bacterial surfaces-a clue to serious complications in infectious diseases. Nat Med 4: 298-302.
83. Hiemstra P, Daha M & Bouma B (1985) Activation of factor B of the complement system by kallikrein and its light chain. Thromb Res 38: 491-503.
84. Hind CR, Collins PM, Baltz ML & Pepys MB (1985) Human serum amyloid P component, a circulating lectin with specificity for the cyclic 4, 6-pyruvate acetal of galactose. Interactions with various bacteria. Biochem J 225: 107-111.
85. Holmskov U, Malhotra R, Sim RB & Jensenius JC (1994) Collectins: collagenous C-type lectins of the innate immune defense system. Immunol Today 15: 67-74.
86. Holmskov U, Thiel S & Jensenius JC (2003) Collectins and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol 21: 547-578.
87. Hong M & Payne SM (1997) Effect of mutations in Shigella flexneri chromosomal and plasmid-encoded lipopolysaccharide genes on invasion and serum resistance. Mol Microbiol 24: 779-791.
88. Hu VW, Esser AF, Podack ER & Wisnieski BJ (1981) The membrane attack mechanism of complement: photolabeling reveals insertion of terminal proteins into target membrane. J Immunol 127: 380-386.
89. Huber-Lang M, Sarma JV, Zetoune FS et al. (2006) Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 12: 682-687.
90. Imamura T, Tanase S, Szmyd G, Kozik A, Travis J & Potempa J (2005) Induction of vascular leakage through release of bradykinin and a novel kinin by cysteine proteinases from Staphylococcus aureus. J Exp Med 201: 1669-1676.
91. Itoh S, Yokoyama R, Kamoshida G, Fujiwara T, Okada H, Takii T, Tsuji T, Fujii S, Hashizume H & Onozaki K (2013) Staphylococcal superantigen-like protein 10 (SSL10) inhibits blood coagulation by binding to prothrombin and factor Xa via their γ-carboxyglutamic acid (Gla) domain. J Biol Chem 288: 21569-21580.
92. Jack DL, Jarvis GA, Booth CL, Turner MW & Klein NJ (2001a) Mannose-binding lectin accelerates complement activation and increases serum killing of Neisseria meningitidis serogroup C. J Infect Dis 184: 836-845.
93. Jack DL, Klein NJ & Turner MW (2001b) Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis. Immunol Rev 180: 86-99.
94. Janssen BJC, Christodoulidou A, McCarthy A, Lambris JD & Gros P (2006) Structure of C3b reveals conformational changes that underlie complement activity. Nature 444: 213-216.
95. Janssen BJC & Gros P (2007) Structural insights into the central complement component C3. Mol Immunol 44: 3-10.
96. Janssen BJC, Huizinga EG, Raaijmakers HCA, Roos A, Daha MR, Nilsson-Ekdahl K, Nilsson B & Gros P (2005) Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 437: 505-511.
97. Joiner KA, Brown EJ & Frank MM (1984) Complement and bacteria: chemistry and biology in host defense. Annu Rev Immunol 2: 461-491.
98. Joiner KA, Hammer CH, Brown EJ, Cole RJ & Frank MM (1982a) Studies on the mechanism of bacterial resistance to complement-mediated killing I. Terminal complement components are deposited and released from Salmonella minnesota S218 without causing bacterial death. J Exp Med 155: 797-808.
99. Joiner KA, Hammer CH, Brown EJ & Frank MM (1982b) Studies on the mechanism of bacterial resistance to complement-mediated killing II. C8 and C9 release C5b67 from the surface of Salmonella minnesota S218 because the Terminal Complex does not insert into the bacterial outer membrane. J Exp Med 155: 809-819.
100. Joiner KA, Schmetz MA, Sanders ME, Murray TG, Hammer CH, Dourmashkin R & Frank MM (1985) Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9. P Natl Acad Sci USA 82: 4808-4812.
101. Joiner KA, Tartanian AB, Hammer CH & Schweinle JE (1989) Multimeric C9 within C5b-9 deposits in unique locations in the cell wall of Salmonella typhimurium. J Immunol 142: 4450-4457.
102. De Jong HK, van der Poll T & Wiersinga WJ (2010) The systemic pro-inflammatory response in sepsis. J Innate Immun 2: 422-430.
103. Jongerius I, Köhl J, Pandey MK, Ruyken M, van Kessel KPM, van Strijp JAG & Rooijakkers SHM (2007) Staphylococcal complement evasion by various convertase-blocking molecules. J Exp Med 204: 2461-2471.
104. Kahler CM, Martin LE, Shih GC, Rahman MM, Carlson RW & Stephens DS (1998) The (a2-8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum. Infect Immun 66: 5939-5947.
105. Kalter ES, van Dijk WC, Timmerman A, Verhoef J & Bouma B (1983) Activation of purified human plasma prekallikrein triggered by cell wall fractions of Escherichia coli and Staphylococcus aureus. J Infect Dis 4: 682-691.
106. Kang M, Ko Y-P, Liang X, Ross CL, Liu Q, Murray BE & Höök M (2013) Collagen-binding microbial surface components recognizing adhesive matrix molecule (MSCRAMM) of Gram-positive bacteria inhibit complement activation via the classical pathway. J Biol Chem 288: 20520-20531.
107. Kaplan AP & Ghebrehiwet B (2010) The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol 47: 2161-2169.
108. Kashyap DR, Wang M, Liu L-H, Boons G-J, Gupta D & Dziarski R (2011) Peptidoglycan recognition proteins kill bacteria by activating protein-sensing two-component systems. Nat Med 17: 676-683.
109. Kellenberger E (1990) The "Bayer bridges" confronted with results from improved electron microscopy methods. Mol Microbiol 4: 697-705.
110. Kemper C & Atkinson JP (2007) T-cell regulation: with complements from innate immunity. Nat Rev Immunol 7: 9-18.
111. Kemper C, Atkinson JP & Hourcade DE (2010) Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol 28: 131-155.
112. Kim K-S, Rao NN, Fraley CD & Kornberg A (2002) Inorganic polyphosphate is essential for long-term survival and virulence factors in Shigella and Salmonella spp. P Natl Acad Sci USA 99: 7675-7680.
113. Ko YP, Kuipers A, Freitag CM, Jongerius I, Medina E, van Rooijen WJ, Spaan AN, van Kessel KP, Höök M & Rooijakkers SH (2013) Phagocytosis escape by a Staphylococcus aureus protein that connects complement and coagulation proteins at the bacterial surface. PLoS Pathog 9: e1003816.
114. Ko Y-P, Liang X, Smith CW, Degen JL & Höök M (2011) Binding of Efb from Staphylococcus aureus to fibrinogen blocks neutrophil adherence. J Biol Chem 286: 9865-9874.
115. Von Köckritz-Blickwede M, Konrad S, Foster S, Gessner JE & Medina E (2010) Protective role of complement C5a in an experimental model of Staphylococcus aureus bacteremia. J Innate Immun 2: 87-92.
116. Kollman JM, Pandi L, Sawaya MR, Riley M & Doolittle RF (2009) Crystal structure of human fibrinogen. Biochemistry 48: 3877-3886.
117. Kowalska K, Carr DB & Lipkowski AW (2002) Direct antimicrobial properties of substance P. Life Sci 71: 747-750.
118. Krarup A, Gulla KC, Gál P, Hajela K & Sim RB (2008) The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen. Biochim Biophys Acta 1784: 1294-1300.
119. Krarup A, Wallis R, Presanis JS, Gál P & Sim RB (2007) Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE 2: e623.
120. Krem MM, Rose T & Di Cera E (2000) Sequence determinants of function and evolution in serine proteases. Trends Cardiovasc Med 10: 171-176.
121. Krisinger MJ, Goebeler V, Lu Z, Meixner SC, Myles T, Pryzdial ELG & Conway EM (2012) Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 120: 1717-1725.
122. Kroll HP, Bhakdi S & Taylor PW (1983) Membrane changes induced by exposure of Escherichia coli to human serum. Infect Immun 42: 1055-1066.
123. Krych-Goldberg M & Atkinson JP (2001) Structure-function relationships of complement receptor type 1. Immunol Rev 180: 112-122.
124. Kukkonen M, Lähteenmäki K, Suomalainen M, Kalkkinen N, Emödy L, Lång H & Korhonen TK (2001) Protein regions important for plasminogen activation and inactivation of alpha2-antiplasmin in the surface protease Pla of Yersinia pestis. Mol Microbiol 40: 1097-1111.
125. Lambris JD, Ricklin D & Geisbrecht BV (2008) Complement evasion by human pathogens. Nat Rev Microbiol 6: 132-142.
126. Langley R, Wines B, Willoughby N, Proft T, Fraser JD & Basu I (2005) The Staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-FcaRI binding and serum killing of bacteria. J Immunol 174: 2926-2933.
127. Law SKA & Dodds AW (1997) The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci 6: 263-274.
128. Law SKA, Minich TM & Levine RP (1981) Binding reaction between the third human complement protein and small molecules. Biochemistry 20: 7457-7463.
129. Law SKA, Minich TM & Levine RP (1984) Covalent binding efficiency of the third and fourth complement proteins in relation to pH, nucleophilicity, and availability of hydroxyl groups. Biochemistry 23: 3267-3272.
130. Leduc I, Olsen B & Elkins C (2009) Localization of the domains of the Haemophilus ducreyi trimeric autotransporter DsrA involved in serum resistance and binding to the extracellular matrix proteins fibronectin and vitronectin. Infect Immun 77: 657-666.
131. Letho T & Meri S (1993) Interactions of soluble CD59 with the terminal complement complexes. J Immunol 151: 4941-4949.
132. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Büller HR, van Deventer SJ, Hack CE, ten Cate JW & Rosenberg RD (1994) Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 93: 114-120.
133. Loh E, Kugelberg E, Tracy A, Zhang Q, Gollan B, Ewles H, Chalmers R, Pelicic V & Tang CM (2013) Temperature triggers immune evasion by Neisseria meningitidis. Nature 502: 237-240.
134. Loof T, Mörgelin M, Johansson L, Oehmcke S, Olin A, Dickneite G, Norrby-Teglund A, Theopold U & Herwald H (2011) Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood 118: 2589-2598.
135. Loos M & Clas F (1987) Antibody-independent killing of gram-negative bacteria via the classical pathway of complement. Immunol Lett 14: 203-208.
136. Loos M, Clas F & Fischer W (1986) Interaction of purified lipoteichoic acid with the classical complement pathway. Infect Immun 53: 595-599.
137. Lovelace LL, Cooper CL, Sodetz JM & Lebioda L (2011) Structure of human C8 protein provides mechanistic insight into membrane pore formation by complement. J Biol Chem 286: 17585-17592.
138. Ma YG, Cho MY, Zhao M, Park JW, Matsushita M, Fujita T & Lee BL (2004) Human mannose-binding lectin and L-ficolin function as specific pattern recognition proteins in the lectin activation pathway of complement. J Biol Chem 279: 25307-25312.
139. Ma YJ, Doni A, Skjoedt M-O, Honoré C, Arendrup M, Mantovani A & Garred P (2011) Heterocomplexes of mannose-binding lectin and the pentraxins PTX3 or serum amyloid P component trigger cross-activation of the complement system. J Biol Chem 286: 3405-3417.
140. Ma YJ, Skjoedt M-O & Garred P (2013) Collectin-11/MASP complex formation triggers activation of the lectin complement pathway-the fifth lectin pathway initiation complex. J Innate Immun 5: 242-250.
141. Macheboeuf P, Buffalo C & Fu C (2011) Streptococcal M1 protein constructs a pathological host fibrinogen network. Nature 472: 64-68.
142. Mandle RJ, Colman RW & Kaplan AP (1976) Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. P Natl Acad Sci USA 73: 4179-4183.
143. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE & Lambris JD (2007) Complement and coagulation: strangers or partners in crime? Trends Immunol 28: 184-192.
144. Martinez RJ & Carroll SF (1980) Sequential metabolic expressions of the lethal process in human serum-treated Escherichia coli: role of lysozyme. Infect Immun 28: 735-745.
145. Matsushita M & Fujita T (2001) Ficolins and the lectin complement pathway. Immunol Rev 180: 78-85.
146. Matsushita M, Endo Y & Fujita T (2013) Structural and functional overview of the lectin complement pathway: its molecular basis and physiological implication. Arch Immunol Ther Exp (Warsz) 61: 273-283.
147. Mattsson E, Herwald H, Cramer H, Persson K, Sjöbring U & Björck L (2001) Staphylococcus aureus induces release of bradykinin in human plasma. Infect Immun 69: 3877-3882.
148. McAdow M, Kim HK, Dedent AC, Hendrickx APA, Schneewind O & Missiakas DM (2011) Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. PLoS Pathog 7: e1002307.
149. McAdow M, Missiakas DM & Schneewind O (2012) Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun 4: 141-148.
150. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG & Waldmann H (1990) Human protectin (CD59), an 18000-20000 MW complement lysis estricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71: 1-9.
151. Merino S, Nogueras MM, Aguilar A, Rubires X, Albertí S, Benedí VJ & Tomás JM (1998) Activation of the complement classical pathway (C1q Binding) by mesophilic Aeromonas hydrophila outer membrane protein. Infect Immun 66: 3825-3831.
152. Merino S, Camprubí S, Albertí S, Benedí VJ & Tomás JM (1992) Mechanisms of Klebsiella pneumoniae resistance to complement-mediated killing. Infect Immun 60: 2529-2535.
153. Milis L, Morris CA, Sheehan MC, Charlesworth JA & Pussell BA (1993) Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9. Clin Exp Immunol 92: 114-119.
154. Mintz CS, Arnold PI, Johnson W & Schultz DR (1995) Antibody-independent binding of complement component C1q by Legionella pneumophila. Infect Immun 63: 4939-4943.
155. Monahan JB & Sodetz JM (1981) Role of the beta subunit in interaction of the eighth component of human complement with the membrane-bound cytolytic complex. J Biol Chem 256: 3258-3262.
156. Morrissey JH, Choi SH & Smith SA (2012) Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood 119: 5972-5979.
157. Mullarky IK, Szaba FM, Berggren KN, Parent MA, Kummer LW, Chen W, Johnson LL & Smiley ST (2005) Infection-stimulated fibrin deposition controls hemorrhage and limits hepatic bacterial growth during listeriosis infection-stimulated fibrin deposition controls hemorrhage and limits hepatic bacterial growth during listeriosis. Infect Immun 73: 3888-3895.
158. Müller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, Schmidbauer S, Gahl WA, Morrissey JH & Renné T (2009) Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139: 1143-1156.
159. Müller-Eberhard HJ (1985) The killer molecule of complement. J Invest Dermatol 85: 47-52.
160. Müller-Eberhard HJ (1986) The membrane attack complex of complement. Annu Rev Immunol 4: 503-528.
161. Murray GL, Attridge SR & Morona R (2005) Inducible serum resistance in Salmonella typhimurium is dependent on wzz(fepE)-regulated very long O antigen chains. Microbes Infect 7: 1296-1304.
162. Nickel KF & Renné T (2012) Crosstalk of the plasma contact system with bacteria. Thromb Res 130(suppl): S78-S83.
163. Nordahl EA, Rydengård V, Mörgelin M & Schmidtchen A (2005) Domain 5 of high molecular weight kininogen is antibacterial. J Biol Chem 280: 34832-34839.
164. Nordahl EA, Rydengård V, Nyberg P, Nitsche DP, Mörgelin M, Malmsten M, Björck L & Schmidtchen A (2004) Activation of the complement system generates antibacterial peptides. P Natl Acad Sci USA 101: 16879-16884.
165. Noursadeghi M, Bickerstaff MC, Gallimore JR, Herbert J, Cohen J & Pepys MB (2000) Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. P Natl Acad Sci USA 97: 14584-14589.
166. Oikonomopoulou K, Ricklin D, Ward PA & Lambris JD (2012) Interactions between coagulation and complement-their role in inflammation. Semin Immunopathol 34: 151-165.
167. Osaki T & Kawabata S (2004) Structure and function of coagulogen, a clottable protein in horseshoe crabs. Cell Mol Life Sci 61: 1257-1265.
168. Påhlman LI, Marx PF, Mörgelin M, Lukomski S, Meijers JCM & Herwald H (2007) Thrombin-activatable fibrinolysis inhibitor binds to Streptococcus pyogenes by interacting with collagen-like proteins A and B. J Biol Chem 282: 24873-24881.
169. Påhlman LI, Mörgelin M, Kasetty G, Olin AI, Schmidtchen A & Herwald H (2013) Antimicrobial activity of fibrinogen and fibrinogen-derived peptides-a novel link between coagulation and innate immunity. Thromb Haemost 109: 930-939.
170. Païdassi H, Tacnet-Delorme P, Lunardi T, Arlaud GJ, Thielens NM & Frachet P (2008) The lectin-like activity of human C1q and its implication in DNA and apoptotic cell recognition. FEBS Lett 582: 3111-3116.
171. Pancholi V & Fischetti VA (1998) alpha -Enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci. J Biol Chem 273: 14503-14515.
172. Pangburn MK & Rawal N (2002) Structure and function of complement C5 convertase enzymes. Biochem Soc Trans 30: 1006-1010.
173. Pangburn MK, Schreiber RD & Müller-Eberhard HJ (1981) Formation of the initial C3 convertase of the alternative complement pathway. J Exp Med 154: 856-867.
174. Papareddy P, Rydengård V, Pasupuleti M, Walse B, Mörgelin M, Chalupka A, Malmsten M & Schmidtchen A (2010) Proteolysis of human thrombin generates novel host defense peptides. PLoS Pathog 6: e1000857.
175. Park KH, Kurokawa K, Zheng L et al. (2010) Human serum mannose-binding lectin senses wall teichoic acid Glycopolymer of Staphylococcus aureus, which is restricted in infancy. J Biol Chem 285: 27167-27175.
176. Pausa M, Pellis V, Cinco M, Giulianini PG, Presani G, Perticarari S, Murgia R & Tedesco F (2003) Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule. J Immunol 170: 3214-3222.
177. Perkins R, Ngo MD, Mahdi F & Shariat-Madar Z (2008) Identification of lipopolysaccharide binding site on high molecular weight kininogen. Biochem Biophys Res Commun 366: 938-943.
178. Persson K, Russell W, Mörgelin M & Herwald H (2003) The conversion of fibrinogen to fibrin at the surface of curliated Escherichia coli bacteria leads to the generation of proinflammatory fibrinopeptides. J Biol Chem 278: 31884-31890.
179. Pilz D, Vocke T, Heesemann J & Brade V (1992) Mechanism of YadA-mediated serum resistance of Yersinia enterocolitica serotype O3. Infect Immun 60: 189-195.
180. Pixley RA, De La Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor FBJ & Colman RW (1993) The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 91: 61-68.
181. Podack ER, Esser AF, Biesecker G & Müller-Eberhard HJ (1980) Membrane attack complex of complement: a structural analysis of its assembly. J Exp Med 151: 301-313.
182. Podack ER, Kolb WP & Muller-Eberhard HJ (1977) The SC5b-7 complex: formation, isolation, properties, and subunit composition. J Immunol 119: 2024-2029.
183. Podack ER, Stoffel W, Esser AF & Müller-Eberhard HJ (1981) Membrane attack complex of complement: distribution of subunits between the hydrocarbon phase of target membranes and water. P Natl Acad Sci USA 78: 4544-4548.
184. Podack ER & Tschopp J (1982a) Circular polymerization of the ninth component of complement. Ring closure of the tubular complex confers resistance to detergent dissociation and to proteolytic degradation. J Biol Chem 257: 15204-15212.
185. Podack ER & Tschopp J (1982b) Polymerization of the ninth component of complement (C9): formation of poly(C9) with a tubular ultrastructure resembling the membrane attack complex of complement. P Natl Acad Sci USA 79: 574-578.
186. Polotsky VY, Fischer W, Ezekowitz RA & Joiner KA (1996) Interactions of human mannose-binding protein with lipoteichoic acids. Infect Immun 64: 380-383.
187. Pramoonjago P, Kaneko M, Kinoshita T, Ohtsubo E, Takeda J, Hong K, Inagi R & Inoue K (1992) Role of TraT protein, an anticomplementary protein produced in Escherichia coli by R100 factor, in serum resistance. J Immunol 148: 827-836.
188. Preissner KT (1991) Structure and biological role of Vitronectin. Annu Rev Cell Biol 7: 275-310.
189. Preissner KT, Podack ER & Müller-Eberhard HJ (1985) The membrane attack complex of complement: relation of C7 to the metastable membrane binding site of the intermediate complex C5b-7. J Immunol 135: 445-451.
190. Rao N & Kornberg A (1996) Inorganic polyphosphate supports resistance and survival of stationary-phase Escherichia coli. J Bacteriol 178: 1394-1400.
191. Rautemaa R, Jarvis GA, Marnila P & Meri S (1998) Acquired resistance of Escherichia coli to complement lysis by binding of glycophosphoinositol-anchored protectin (CD59). Infect Immun 66: 1928-1933.
192. Rautemaa R & Meri S (1999) Complement-resistance mechanisms of bacteria. Microbes Infect 1: 785-794.
193. Rautemaa R, Rautelin H, Puolakkainen P, Kokkola A, Karkkainen P & Meri S (2001) Survival of Helicobacter pylori from complement lysis by binding of GPI-anchored protectin (CD59). Gastroenterology 120: 470-479.
194. Rawal N & Pangburn MK (2001) Structure/function of C5 convertases of complement. Int Immunopharmacol 1: 415-422.
195. Reddigari S & Kaplan AP (1988) Cleavage of human high-molecular weight kininogen by purified kallikreins and upon contact activation of plasma. Blood 71: 1334-1340.
196. Reichel CA, Kanse SM & Krombach F (2012) At the interface of fibrinolysis and inflammation: the role of urokinase-type plasminogen activator in the leukocyte extravasation cascade. Trends Cardiovasc Med 22: 192-196.
197. Reichmann NT & Gründling A (2011) Location, synthesis and function of glycolipids and polyglycerolphosphate lipoteichoic acid in Gram-positive bacteria of the phylum Firmicutes. FEMS Microbiol Lett 319: 97-105.
198. Ricklin D, Hajishengallis G, Yang K & Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11: 785-797.
199. Riley SP, Patterson JL, Nava S & Martinez JJ (2013) Pathogenic Rickettsia species acquire vitronectin from human serum to promote resistance to complement-mediated killing. Cell Microbiol 16: 849-861.
200. Ringnér M, Paulsson M & Wadström T (1992) Vitronectin binding by Helicobacter pylori. FEMS Microbiol Immunol 105: 219-224.
201. Ringstad L, Kacprzyk L, Schmidtchen A & Malmsten M (2007) Effects of topology, length, and charge on the activity of a kininogen-derived peptide on lipid membranes and bacteria. Biochim Biophys Acta 1768: 715-727.
202. Rollins SA & Sims PJ (1990) The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 144: 3478-3483.
203. Rooijakkers SHM, Ruyken M, Roos A, Daha MR, Presanis JS, Sim RB, van Wamel WJB, van Kessel KPM & van Strijp JAG (2005) Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat Immunol 6: 920-927.
204. Rosado CJ, Kondos S, Bull TE et al. (2008) The MACPF/CDC family of pore-forming toxins. Cell Microbiol 10: 1765-1774.
205. Rotstein OD (1992) Role of fibrin deposition in the pathogenesis of intraabdominal infection. Eur J Clin Microbiol Infect Dis 11: 1064-1068.
206. Ruiz N, Kahne D & Silhavy TJ (2006) Advances in understanding bacterial outer-membrane biogenesis. Nat Rev Microbiol 4: 57-66.
207. Sa E Cunha C, Griffiths NJ & Virji M (2010) Neisseria meningitidis Opc invasin binds to the sulphated tyrosines of activated vitronectin to attach to and invade human brain endothelial cells. PLoS Pathog 6: e1000911.
208. Sahu A & Pangburn MK (1995) Tyrosine is a potential site for covalent attachment of activated complement component C3. Mol Immunol 32: 711-716.
209. Samuel M, Pixley R, Villanuevat M, Colman R & Villanueva G (1992) Human factor XII (Hageman factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies. J Biol Chem 267: 19691-19697.
210. Schindler MKH, Schütz MS, Mühlenkamp MC, Rooijakkers SHM, Hallström T, Zipfel PF & Autenrieth IB (2012) Yersinia enterocolitica YadA mediates complement evasion by recruitment and inactivation of C3 products. J Immunol 189: 4900-4908.
211. Schmaier A & McCrae K (2007) The plasma kallikrein-kinin system: its evolution from contact activation. J Thromb Haemost 5: 2323-2329.
212. Schneider MC, Exley RM, Ram S, Sim RB & Tang CM (2007) Interactions between Neisseria meningitidis and the complement system. Trends Microbiol 15: 233-240.
213. Scott C & Silver L (1984) Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor. J Clin Invest 73: 954-962.
214. Scott CF & Colman RW (1980) Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma. J Clin Invest 65: 413-421.
215. Shpacovitch V, Feld M, Hollenberg MD, Luger TA & Steinhoff M (2008) Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J Leukoc Biol 83: 1309-1322.
216. Shannon O & Flock J-I (2004) Extracellular fibrinogen binding protein, Efb, from Staphylococcus aureus binds to platelets and inhibits platelet aggregation. Thromb Haemost 91: 779-789.
217. Shiver JW, Dankert JR & Esser AF (1991) Formation of ion-conducting channels by the membrane attack complex proteins of complement. Biophys J 60: 761-769.
218. Siebenlist KR, Meh DA & Mosesson MW (2001) Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin. Thromb Haemost 86: 1221-1228.
219. Silasi-Mansat R, Zhu H, Popescu NI et al. (2010) Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116: 1002-1010.
220. Silhavy TJ, Kahne D & Walker S (2010) The bacterial cell envelope. Cold Spring Harb Perspect Biol 2: a000414.
221. Singh B, Blom AM, Unal C, Nilson B, Mörgelin M & Riesbeck K (2010a) Vitronectin binds to the head region of Moraxella catarrhalis ubiquitous surface protein A2 and confers complement-inhibitory activity. Mol Microbiol 75: 1426-1444.
222. Singh B, Su Y-C & Riesbeck K (2010b) Vitronectin in bacterial pathogenesis: a host protein used in complement escape and cellular invasion. Mol Microbiol 78: 545-560.
223. Sjölinder H, Eriksson J, Maudsdotter L, Aro H & Jonsson A-B (2008) Meningococcal outer membrane protein NhhA is essential for colonization and disease by preventing phagocytosis and complement attack. Infect Immun 76: 5412-5420.
224. Skerka C, Horstmann RD & Zipfel PF (1991) Molecular cloning of a human serum protein structurally related to complement factor H. J Biol Chem 266: 12015-12020.
225. Skogen WF, Senior RM, Griffin GL & Wilner GD (1988) Fibrinogen-derived peptide B beta 1-42 is a multidomained neutrophil chemoattractant. Blood 71: 1475-1479.
226. Slaney JM, Gallagher A, Aduse-Opoku J, Pell K & Curtis MA (2006) Mechanisms of resistance of Porphyromonas gingivalis to killing by serum complement. Infect Immun 74: 5352-5361.
227. Smeesters PR, McMillan DJ & Sriprakash KS (2010) The streptococcal M protein: a highly versatile molecule. Trends Microbiol 18: 275-282.
228. Smith SA, Choi SH, Davis-Harrison R, Huyck J, Boettcher J, Rienstra CM & Morrissey JH (2010) Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 116: 4353-4359.
229. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R & Morrissey JH (2006) Polyphosphate modulates blood coagulation and fibrinolysis. P Natl Acad Sci USA 103: 903-908.
230. Spitzer D, Mitchell LM, Atkinson JP & Hourcade DE (2007) Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol 179: 2600-2608.
231. Steckel EW, Welbaum BE & Sodetzs JM (1983) Evidence of direct insertion of terminal complement proteins into cell membrane bilayers during cytolysis. J Biol Chem 258: 4318-4324.
232. Stewart JL, Kolb WP & Sodetz JM (1987) Evidence that C5b recognizes and mediates C8 incorporation into the cytolytic complex of complement. J Immunol 139: 1960-1964.
233. Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC, Yang AY, Rozek LS, Wang X, Sjöbring U & Ginsburg D (2004) Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 305: 1283-1286.
234. Sun H (2006) The interaction between pathogens and the host coagulation system. Physiology 21: 281-288.
235. Sun H, Wang X, Degen JL & Ginsburg D (2009) Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 113: 1358-1364.
236. Tamura N, Shimada A & Chang S (1972) Further evidence for immune cytolysis by antibody and the first eight components of complement in the absence of C9. Immunology 22: 131-140.
237. Tan LA, Yang AC, Kishore U & Sim RB (2011) Interactions of complement proteins C1q and factor H with lipid A and Escherichia coli: further evidence that factor H regulates the classical complement pathway. Protein Cell 2: 320-332.
238. Tapper H & Herwald H (2000) Modulation of hemostatic mechanisms in bacterial infectious diseases. Blood 96: 2329-2337.
239. Taylor FJ, Chang A, Ruf W, Morrissey J, Hinshaw L, Catlett R, Blick K & Edgington T (1991) Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 33: 127-134.
240. Taylor PW (1983) Bactericidal and bacteriolytic activity of serum against Gram-negative bacteria. Microbiol Rev 47: 46-83.
241. Taylor PW & Kroll HP (1983) Killing of an encapsulated strain of Escherichia coli by human serum. Infect Immun 39: 122-131.
242. Thomer L, Schneewind O & Missiakas D (2013) Multiple ligands of von Willebrand Factor binding protein (vWbp) promote Staphylococcus aureus clot formation in human plasma. J Biol Chem 288: 28283-28292.
243. Timmann C, Leippe M & Horstmann RD (1991) Two major serum components antigenically related to complement factor H are different glycosylation forms of a single protein with no factor H-like complement regulatory funtions. J Immunol 146: 1265-1270.
244. Tomlinson S, Taylor PW & Luzio JP (1990) Transfer of preformed terminal C5b-9 complement complexes into the outer membrane of viable Gram-negative bacteria: effect on viability and integrity. Biochemistry 29: 1852-1860.
245. Tschopp J (1984) Circular polymerization of the membranolytic ninth component of complement. Dependence on metal ions. J Biol Chem 259: 10569-10573.
246. Tschopp J, Masson D & Stanley KK (1986) Structural/functional similarity between proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis. Nature 322: 831-834.
247. Tschopp J, Podack ER & Müller-Eberhard HJ (1985) The membrane attack complex of complement: C5b-8 complex as accelerator of C9 polymerization. J Immunol 134: 495-499.
248. Turner RD, Hurd AF, Cadby A, Hobbs JK & Foster SJ (2013) Cell wall elongation mode in Gram-negative bacteria is determined by peptidoglycan architecture. Nat Commun 4: 1496.
249. Tweten RK (2005) Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Infect Immun 73: 6199-6209.
250. Uchiyama S, Andreoni F, Zürcher C et al. (2013) Coiled-coil irregularities of the M1 protein structure promote M1-fibrinogen interaction and influence group A Streptococcus host cell interactions and virulence. J Mol Med 91: 861-869.
251. Väkevä A, Jauhiainen M, Ehnholm C, Lehto T & Meri S (1994) High-density lipoproteins can act as carriers of glycophosphoinositol lipid-anchored CD59 in human plasma. Immunology 4: 28-33.
252. van der Poll T, Levi M, Hack CE et al. (1994) Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 179: 1253-1259.
253. van der Poll T, Levi M, Büller HR, van Deventer SJH, de Boer JP, Hack CE & ten Cate JW (1991) Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 174: 729-732.
254. van der Poll T & Opal SM (2008) Host-pathogen interactions in sepsis. Lancet Infect Dis 8: 32-43.
255. Verbrugh HA, van Dijk WC, Peters R, van Erne ME, Daha MR, Peterson PK & Verhoef J (1980) Opsonic recognition of staphylococci mediated by cell wall peptidoglycan: antibody-independent activation of human complement and opsonic activity of peptidoglycan antibodies. J Immunol 124: 1167-1173.
256. Vik DP & Fearon DT (1985) Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3. J Immunol 134: 2571-2579.
257. Vogel U, Weinberger A, Frank R, Müller A, Köhl J, Atkinson JP & Frosch M (1997) Complement factor C3 deposition and serum resistance in isogenic capsule and lipooligosaccharide sialic acid mutants of serogroup B Neisseria meningitidis. Infect Immun 65: 4022-4029.
258. Volanakis JE (2001) Human C-reactive protein: expression, structure, and function. Mol Immunol 38: 189-197.
259. Vollmer W, Blanot D & de Pedro MA (2008) Peptidoglycan structure and architecture. FEMS Microbiol Rev 32: 149-167.
260. Walport MJ (2001) Complement first of two parts. N Engl J Med 344: 1058-1066.
261. Wang Y, Bjes ES & Esser AF (2000) Molecular aspects of complement-mediated bacterial killing. Periplasmic conversion of C9 from a protoxin to a toxin. J Biol Chem 275: 4687-4692.
262. Wang Z, Wilhelmsson C, Hyrsl P et al. (2010) Pathogen entrapment by transglutaminase-a conserved early innate immune mechanism. PLoS Pathog 6: e1000763.
263. Wat JM, Foley JH, Krisinger MJ et al. (2014) Polyphosphate suppresses complement via the terminal pathway. Blood 123: 768-776.
264. Wollein Waldetoft K, Svensson L, Mörgelin M, Olin AI, Nitsche-Schmitz DP, Björck L & Frick I-M (2012) Streptococcal surface proteins activate the contact system and control its antibacterial activity. J Biol Chem 287: 25010-25018.
265. Wright SD & Levine RP (1981a) How complement kills E. coli. I. Location of the lethal lesion. J Immunol 127: 1146-1151.
266. Wright SD & Levine RP (1981b) How complement kills E. coli II. The apparent two-hit nature of the lethal event. J Immunol 127: 1152-1156.
267. Wu J, Wu Y-Q, Ricklin D, Janssen BJC, Lambris JD & Gros P (2009) Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol 10: 728-733.
268. Wuepper K & Cochrane C (1972) Plasma prekallikrein: isolation, characterization, and mechanism of activation. J Exp Med 135: 1-20.
269. Yang Z, Mochalkin I & Doolittle RF (2000) A model of fibrin formation based on crystal structures of fibrinogen and fibrin fragments complexed with synthetic peptides. P Natl Acad Sci USA 97: 14156-14161.
270. Yoshida T, Yoshioka Y, Tochigi S et al. (2013) Intranasal exposure to amorphous nanosilica particles could activate intrinsic coagulation cascade and platelets in mice. Part Fibre Toxicol 10: 41.
271. Zalman LS & Muller-Eberhard HJ (1990) Comparison of channels formed by poly C9, C5b-8 and the membrane attack complex of complement. Mol Immunol 27: 533-537.
272. Zalman LS, Wood LM & Müller-Eberhard HJ (1986) Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. P Natl Acad Sci USA 83: 6975-6979.
273. Zhang Q, Li Y & Tang CM (2010) The role of the exopolyphosphatase PPX in avoidance by Neisseria meningitidis of complement-mediated killing. J Biol Chem 285: 34259-34268.
274. Zipfel PF, Hallström T & Riesbeck K (2013) Human complement control and complement evasion by pathogenic microbes-tipping the balance. Mol Immunol 56: 152-160.
275. Zipfel PF & Skerka C (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9: 729-740.